Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
10.15
+0.30 (3.05%)
At close: Mar 4, 2026, 4:00 PM EST
10.07
-0.08 (-0.79%)
Pre-market: Mar 5, 2026, 9:04 AM EST
Relay Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Relay Therapeutics stock have an average target of 14.5, with a low estimate of 10 and a high estimate of 19. The average target predicts an increase of 42.86% from the current stock price of 10.15.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Relay Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 6 | 6 | 6 | 6 | 4 |
| Buy | 4 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 9 | 8 | 8 | 8 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $13 → $15 | Buy | Maintains | $13 → $15 | +47.78% | Feb 27, 2026 |
| Oppenheimer | Oppenheimer | Hold → Buy Upgrades $14 | Hold → Buy | Upgrades | $14 | +37.93% | Jan 26, 2026 |
| Wells Fargo | Wells Fargo | Hold → Buy Upgrades $6 → $13 | Hold → Buy | Upgrades | $6 → $13 | +28.08% | Dec 12, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $4 → $6 | Hold | Maintains | $4 → $6 | -40.89% | Nov 7, 2025 |
| Guggenheim | Guggenheim | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +47.78% | Sep 4, 2025 |
Financial Forecast
Revenue This Year
8.08M
from 15.36M
Decreased by -47.35%
Revenue Next Year
22.51M
from 8.08M
Increased by 178.50%
EPS This Year
-1.71
from -1.61
EPS Next Year
-1.74
from -1.71
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 42.2M | 112.7M | |||
| Avg | 8.1M | 22.5M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 174.9% | 1,294.0% | |||
| Avg | -47.4% | 178.5% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.41 | -1.37 | |||
| Avg | -1.71 | -1.74 | |||
| Low | -2.24 | -2.42 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.